Skip to main content
Premium Trial:

Request an Annual Quote

Celera, ABI to Split on July 1

NEW YORK (GenomeWeb News) – Applera said today that its two groups, Celera and Applied Biosystems, would be formally separated on July 1.
 
The firm said that the board of directors approved the proposed separation, which will be accomplished by the redemption of all outstanding shares of Celera’s stock. Each share of the current Celera tracking stock will be exchanged for one share of the independent Celera Corp.
 
Last month, Celera filed with the US Securities and Exchange Commission a preliminary prospectus to split off from parent company Applera. Officials from both Celera and ABI have hinted for months that a split of the two companies would be the likely outcome ofa review begun in August by investment firm Morgan Stanley, which was hired to explore options for restructuring the groups.
 
Completion of the split is subject to a number of conditions including "an opinion from counsel to Applera regarding the tax consequences of the separation," as well as the SEC declaring effective Celera's registration statement on or prior to June 15.
 
Kathy Ordoñez, the current president of Celera, will become CEO of the firm, which will retain its headquarters in Alameda, Calif. Celera will trade on the NASDAQ.
 
ABI will continue to trade on the New York Stock Exchange.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.